EMA - Phasing out of extraordinary COVID-19 regulatory flexibilities

19th July 2023

EMA - Phasing out of extraordinary COVID-19 regulatory flexibilities

EMA, the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the extraordinary regulatory flexibilities for medicines put in place during the COVID-19 pandemic to help address regulatory and supply challenges arising from the pandemic. This follows the end of the COVID-19 public health emergency declared by WHO in May 2023. 

View More

Back to News Archive